Empagliflozin In Type 2 Diabetes: Added Benefit Not Proven

Share this content:
Empagliflozin in type 2 diabetes: Added benefit not proven
Empagliflozin in type 2 diabetes: Added benefit not proven
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapies in these patient groups.
READ FULL ARTICLE From Medical Express
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




is free, fast, and customized just for you!




Already a member?

Sign In Now »